Cargando…

A multicenter, prospective, randomized, controlled trial evaluating the safety and efficacy of intracoronary cell infusion mobilized with granulocyte colony-stimulating factor and darbepoetin after acute myocardial infarction: study design and rationale of the 'MAGIC cell-5-combination cytokine trial'

BACKGROUND: Bone marrow derived stem/progenitor cell transplantation after acute myocardial infarction is safe and effective for improving left ventricular systolic function. However, the improvement of left ventricular systolic function is limited. This study will evaluate novel stem/progenitor cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Hyun-Jae, Kim, Min-Kyung, Kim, Myung-Gon, Choi, Dong-Ju, Yoon, Jung-Han, Park, Young-Bae, Kim, Hyo-Soo
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3045901/
https://www.ncbi.nlm.nih.gov/pubmed/21299845
http://dx.doi.org/10.1186/1745-6215-12-33
_version_ 1782198880975192064
author Kang, Hyun-Jae
Kim, Min-Kyung
Kim, Myung-Gon
Choi, Dong-Ju
Yoon, Jung-Han
Park, Young-Bae
Kim, Hyo-Soo
author_facet Kang, Hyun-Jae
Kim, Min-Kyung
Kim, Myung-Gon
Choi, Dong-Ju
Yoon, Jung-Han
Park, Young-Bae
Kim, Hyo-Soo
author_sort Kang, Hyun-Jae
collection PubMed
description BACKGROUND: Bone marrow derived stem/progenitor cell transplantation after acute myocardial infarction is safe and effective for improving left ventricular systolic function. However, the improvement of left ventricular systolic function is limited. This study will evaluate novel stem/progenitor cell therapy with combination cytokine treatment of the long-acting erythropoietin analogue, darbepoetin, and granulocyte colony-stimulating factor (G-CSF) in patients with acute myocardial infarction. METHODS: The 'MAGIC Cell-5-Combination Cytokine Trial' is a multicenter, prospective, randomized, 3-arm, controlled trial with blind evaluation of the endpoints. A total of 116 patients will randomly receive one of the following three treatments: an intravenous darbepoetin infusion and intracoronary infusion of peripheral blood stem cells mobilized with G-CSF (n = 58), an intracoronary infusion of peripheral blood stem cells mobilized with G-CSF alone (n = 29), or conventional therapy (n = 29) at phase I. Patients with left ventricular ejection fraction < 45% at 6 months, in the patients who received stem cell therapy at phase I, will receive repeated cell therapy at phase II. The objectives of this study are to evaluate the safety and efficacy of combination cytokine therapy with erythropoietin and G-CSF (phase I) and repeated progenitor/stem cell treatment (phase II). DISCUSSION: This is the first study to evaluate the safety and efficacy of combination cytokine based progenitor/stem cell treatment. TRIAL REGISTRATION: http://www.ClinicalTrials.gov identifier: NCT00501917.
format Text
id pubmed-3045901
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30459012011-03-01 A multicenter, prospective, randomized, controlled trial evaluating the safety and efficacy of intracoronary cell infusion mobilized with granulocyte colony-stimulating factor and darbepoetin after acute myocardial infarction: study design and rationale of the 'MAGIC cell-5-combination cytokine trial' Kang, Hyun-Jae Kim, Min-Kyung Kim, Myung-Gon Choi, Dong-Ju Yoon, Jung-Han Park, Young-Bae Kim, Hyo-Soo Trials Study Protocol BACKGROUND: Bone marrow derived stem/progenitor cell transplantation after acute myocardial infarction is safe and effective for improving left ventricular systolic function. However, the improvement of left ventricular systolic function is limited. This study will evaluate novel stem/progenitor cell therapy with combination cytokine treatment of the long-acting erythropoietin analogue, darbepoetin, and granulocyte colony-stimulating factor (G-CSF) in patients with acute myocardial infarction. METHODS: The 'MAGIC Cell-5-Combination Cytokine Trial' is a multicenter, prospective, randomized, 3-arm, controlled trial with blind evaluation of the endpoints. A total of 116 patients will randomly receive one of the following three treatments: an intravenous darbepoetin infusion and intracoronary infusion of peripheral blood stem cells mobilized with G-CSF (n = 58), an intracoronary infusion of peripheral blood stem cells mobilized with G-CSF alone (n = 29), or conventional therapy (n = 29) at phase I. Patients with left ventricular ejection fraction < 45% at 6 months, in the patients who received stem cell therapy at phase I, will receive repeated cell therapy at phase II. The objectives of this study are to evaluate the safety and efficacy of combination cytokine therapy with erythropoietin and G-CSF (phase I) and repeated progenitor/stem cell treatment (phase II). DISCUSSION: This is the first study to evaluate the safety and efficacy of combination cytokine based progenitor/stem cell treatment. TRIAL REGISTRATION: http://www.ClinicalTrials.gov identifier: NCT00501917. BioMed Central 2011-02-07 /pmc/articles/PMC3045901/ /pubmed/21299845 http://dx.doi.org/10.1186/1745-6215-12-33 Text en Copyright ©2011 Kang et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study Protocol
Kang, Hyun-Jae
Kim, Min-Kyung
Kim, Myung-Gon
Choi, Dong-Ju
Yoon, Jung-Han
Park, Young-Bae
Kim, Hyo-Soo
A multicenter, prospective, randomized, controlled trial evaluating the safety and efficacy of intracoronary cell infusion mobilized with granulocyte colony-stimulating factor and darbepoetin after acute myocardial infarction: study design and rationale of the 'MAGIC cell-5-combination cytokine trial'
title A multicenter, prospective, randomized, controlled trial evaluating the safety and efficacy of intracoronary cell infusion mobilized with granulocyte colony-stimulating factor and darbepoetin after acute myocardial infarction: study design and rationale of the 'MAGIC cell-5-combination cytokine trial'
title_full A multicenter, prospective, randomized, controlled trial evaluating the safety and efficacy of intracoronary cell infusion mobilized with granulocyte colony-stimulating factor and darbepoetin after acute myocardial infarction: study design and rationale of the 'MAGIC cell-5-combination cytokine trial'
title_fullStr A multicenter, prospective, randomized, controlled trial evaluating the safety and efficacy of intracoronary cell infusion mobilized with granulocyte colony-stimulating factor and darbepoetin after acute myocardial infarction: study design and rationale of the 'MAGIC cell-5-combination cytokine trial'
title_full_unstemmed A multicenter, prospective, randomized, controlled trial evaluating the safety and efficacy of intracoronary cell infusion mobilized with granulocyte colony-stimulating factor and darbepoetin after acute myocardial infarction: study design and rationale of the 'MAGIC cell-5-combination cytokine trial'
title_short A multicenter, prospective, randomized, controlled trial evaluating the safety and efficacy of intracoronary cell infusion mobilized with granulocyte colony-stimulating factor and darbepoetin after acute myocardial infarction: study design and rationale of the 'MAGIC cell-5-combination cytokine trial'
title_sort multicenter, prospective, randomized, controlled trial evaluating the safety and efficacy of intracoronary cell infusion mobilized with granulocyte colony-stimulating factor and darbepoetin after acute myocardial infarction: study design and rationale of the 'magic cell-5-combination cytokine trial'
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3045901/
https://www.ncbi.nlm.nih.gov/pubmed/21299845
http://dx.doi.org/10.1186/1745-6215-12-33
work_keys_str_mv AT kanghyunjae amulticenterprospectiverandomizedcontrolledtrialevaluatingthesafetyandefficacyofintracoronarycellinfusionmobilizedwithgranulocytecolonystimulatingfactoranddarbepoetinafteracutemyocardialinfarctionstudydesignandrationaleofthemagiccell5combinationcytokinetr
AT kimminkyung amulticenterprospectiverandomizedcontrolledtrialevaluatingthesafetyandefficacyofintracoronarycellinfusionmobilizedwithgranulocytecolonystimulatingfactoranddarbepoetinafteracutemyocardialinfarctionstudydesignandrationaleofthemagiccell5combinationcytokinetr
AT kimmyunggon amulticenterprospectiverandomizedcontrolledtrialevaluatingthesafetyandefficacyofintracoronarycellinfusionmobilizedwithgranulocytecolonystimulatingfactoranddarbepoetinafteracutemyocardialinfarctionstudydesignandrationaleofthemagiccell5combinationcytokinetr
AT choidongju amulticenterprospectiverandomizedcontrolledtrialevaluatingthesafetyandefficacyofintracoronarycellinfusionmobilizedwithgranulocytecolonystimulatingfactoranddarbepoetinafteracutemyocardialinfarctionstudydesignandrationaleofthemagiccell5combinationcytokinetr
AT yoonjunghan amulticenterprospectiverandomizedcontrolledtrialevaluatingthesafetyandefficacyofintracoronarycellinfusionmobilizedwithgranulocytecolonystimulatingfactoranddarbepoetinafteracutemyocardialinfarctionstudydesignandrationaleofthemagiccell5combinationcytokinetr
AT parkyoungbae amulticenterprospectiverandomizedcontrolledtrialevaluatingthesafetyandefficacyofintracoronarycellinfusionmobilizedwithgranulocytecolonystimulatingfactoranddarbepoetinafteracutemyocardialinfarctionstudydesignandrationaleofthemagiccell5combinationcytokinetr
AT kimhyosoo amulticenterprospectiverandomizedcontrolledtrialevaluatingthesafetyandefficacyofintracoronarycellinfusionmobilizedwithgranulocytecolonystimulatingfactoranddarbepoetinafteracutemyocardialinfarctionstudydesignandrationaleofthemagiccell5combinationcytokinetr
AT kanghyunjae multicenterprospectiverandomizedcontrolledtrialevaluatingthesafetyandefficacyofintracoronarycellinfusionmobilizedwithgranulocytecolonystimulatingfactoranddarbepoetinafteracutemyocardialinfarctionstudydesignandrationaleofthemagiccell5combinationcytokinetri
AT kimminkyung multicenterprospectiverandomizedcontrolledtrialevaluatingthesafetyandefficacyofintracoronarycellinfusionmobilizedwithgranulocytecolonystimulatingfactoranddarbepoetinafteracutemyocardialinfarctionstudydesignandrationaleofthemagiccell5combinationcytokinetri
AT kimmyunggon multicenterprospectiverandomizedcontrolledtrialevaluatingthesafetyandefficacyofintracoronarycellinfusionmobilizedwithgranulocytecolonystimulatingfactoranddarbepoetinafteracutemyocardialinfarctionstudydesignandrationaleofthemagiccell5combinationcytokinetri
AT choidongju multicenterprospectiverandomizedcontrolledtrialevaluatingthesafetyandefficacyofintracoronarycellinfusionmobilizedwithgranulocytecolonystimulatingfactoranddarbepoetinafteracutemyocardialinfarctionstudydesignandrationaleofthemagiccell5combinationcytokinetri
AT yoonjunghan multicenterprospectiverandomizedcontrolledtrialevaluatingthesafetyandefficacyofintracoronarycellinfusionmobilizedwithgranulocytecolonystimulatingfactoranddarbepoetinafteracutemyocardialinfarctionstudydesignandrationaleofthemagiccell5combinationcytokinetri
AT parkyoungbae multicenterprospectiverandomizedcontrolledtrialevaluatingthesafetyandefficacyofintracoronarycellinfusionmobilizedwithgranulocytecolonystimulatingfactoranddarbepoetinafteracutemyocardialinfarctionstudydesignandrationaleofthemagiccell5combinationcytokinetri
AT kimhyosoo multicenterprospectiverandomizedcontrolledtrialevaluatingthesafetyandefficacyofintracoronarycellinfusionmobilizedwithgranulocytecolonystimulatingfactoranddarbepoetinafteracutemyocardialinfarctionstudydesignandrationaleofthemagiccell5combinationcytokinetri